#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Tirzepatide at 6 months: who stays on it
A US claims study of 22,512 tirzepatide starters found 68% still on the drug at six months. Here is what that number does and does not tell you.
Tirzepatide cuts liver fat despite PNPLA3
A post hoc look at SURPASS-3 MRI finds tirzepatide cut liver fat in type 2 diabetes whether or not patients carried the PNPLA3 I148M gene variant.
Can peptides fix a slow metabolism?
A reader on r/peptides asked if peptides could fix years of unexplained weight gain. Here is what GLP-1 drugs actually do, and what to test first.
Can GLP-1 Drugs Help Ulcerative Colitis?
A matched cohort study links semaglutide and liraglutide use to higher ulcerative colitis remission, though neither drug is approved for IBD.
Old retatrutide pen: still safe to use?
Retatrutide is investigational, and even FDA-approved GLP-1 pens must be discarded weeks after first use, not months later.
Orzeyful isn't Ozempic for the brain
The FDA approved oveporexton for narcolepsy in August 2026. It targets the neuropeptide orexin, but the drug itself is not a peptide like semaglutide.
Tirzepatide and a rare skin rash: one case
A 2026 case report describes a chest rash clearing during tirzepatide-associated weight loss. Here is what one patient shows, and does not.
Tirzepatide and Prader-Willi diabetes
A 2026 case report describes tirzepatide easing treatment-resistant diabetes in an adult with Prader-Willi syndrome. Here is what one patient shows.
GLP-1 drugs and erectile dysfunction
A new meta-analysis links GLP-1 drugs like semaglutide and tirzepatide to modest erectile-function gains, though other research disagrees.
GLP-1 Drugs and Psoriasis Healthcare Use
A new JEADV letter examines whether GLP-1 and GLP-1/GIP drugs like tirzepatide and semaglutide change healthcare use in psoriasis patients.
MASLD treatment: what a 2026 review found
A Gut and Liver review maps current MASLD treatment options and a growing pipeline, from lifestyle change to GLP-1 agonists and thyroid receptor drugs.
Oral incretin therapies for weight loss
Oral semaglutide and orforglipron bring GLP-1 based weight management into tablet form. Here is what the evidence does and does not show.